Background: Diabetes is recognized as a “coronary heart disease risk equivalent”. This happens because high rates of dyslipidemia among diabetic patients which is thought to be one of the major factors leading to the high percentage of deaths among diabetics due to cardiovascular disease (CVD).Methods: The study aims to compare the cost effectiveness and tolerance or safety profile of atorvastatin 40 mg daily and rosuvastatin 20 mg daily and on alternate day. This prospective observational study was conducted in 300, type-2 diabetes mellitus patients between November 2013 and 2014.Results: The total CK level increased after 6 weeks among patients on atorvastatin 40 mg, rosuvastatin 20 mg, and rosuvastatin 20 mg alternate day was stastically significant although it was within accepted normal range. None of the patients reported to have muscle symptoms i.e. myalgia. SGOT, SGPT, bilirubin levels with atorvastatin 40 mg were statistically insignificant. Same was the case with rosuvastatin 20 mg daily. However the SGOT and bilrubin level increased with rosuvastatin 20 mg alternate day was statistically significant, but was within normal range, we attribute it to chance. The cost obviously has shown to half in rosuvastatin 20 mg on alternate day.Conclusions: Atorvastatin 40 mg, rosuvastatin 20 mg and rosuvastatin 20 mg alternate day was statically significant (p<.0010). SGOT, SGPT, bilirubin with atorvastatin 40 mg were statistically insignificant. Same was case with rosuvastatin 20 mg daily. SGOT, bilirubin level increased with rosuvastatin 20 mg alternate day was statistically significant. Cost obviously shown to half in rosuvastatin 20 mg alternate day.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.